Pasithea Therapeutics Corp (KTTA)
NASDAQ:KTTA
US Market
Holding KTTA?
Track your performance easily

Pasithea Therapeutics Corp (KTTA) Income Statement

35 Followers

Pasithea Therapeutics Corp Income Statement

Last quarter (Q ), Pasithea Therapeutics Corp's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Pasithea Therapeutics Corp's net income was $-3.87M. See Pasithea Therapeutics Corp’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
--$ 486.56K$ 15.06K$ 0.00
Cost of Revenue
--$ 113.19K$ 17.27K$ 0.00
Gross Profit
--$ 373.36K$ -2.21K$ 0.00
Operating Expense
$ 8.84M$ 15.98M$ 12.59M$ 4.51M$ 40.98K
Operating Income
$ -16.92M$ -15.98M$ -12.59M$ -4.51M$ -40.98K
Net Non Operating Interest Income Expense
$ -526.17K$ -415.37K$ -102.00$ -508.00$ 0.00
Other Income Expense
$ -135.92K$ 56.24K$ 861.09K$ -2.33M-
Pretax Income
$ -16.37M$ -15.51M$ -11.73M$ -2.17M$ -40.98K
Tax Provision
----$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -16.39M$ -15.96M$ -13.94M$ -2.17M$ -40.98K
Basic EPS
$ -14.83$ -13.01$ -11.00$ -4.20$ >-0.01
Diluted EPS
$ -14.83$ -13.01$ -10.60-$ >-0.01
Basic Average Shares
$ 4.38M$ 1.23M$ 1.26M$ 520.23K$ 13.06M
Diluted Average Shares
$ 4.38M$ 1.23M$ 1.26M$ 517.50K$ 13.06M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 15.27M$ 15.98M$ 12.59M$ 4.52M$ 40.98K
Net Income From Continuing And Discontinued Operation
$ -16.39M$ -15.96M$ -13.94M$ -2.17M$ -40.98K
Normalized Income
$ -15.69M$ -17.29M--$ -40.98K
Interest Expense
----$ 0.00
EBIT
$ -8.58M$ -15.98M$ -12.59M$ -2.17M$ -40.98K
EBITDA
$ -7.93M$ -15.33M$ -12.58M$ -2.17M$ -40.98K
Currency in USD

Pasithea Therapeutics Corp Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis